B9972

Hyp - trans-4-hydroxy-L-proline; IgI - alpha(2-indanyl)glycine; Oic - octahydroindole-2-carboxylic acid; TFA -trifluoroacetic acid; bradykinin receptor 2 agonist

Also Known As:

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Cool, Carlyne: 1 article (08/2005)
2.	Demura, Yoshiki: 1 article (08/2005)
3.	Gera, Lajos: 1 article (08/2005)
4.	Kasper, Michael: 1 article (08/2005)
5.	Scerbavicius, Robertas: 1 article (08/2005)
6.	Stewart, John M: 1 article (08/2005)
7.	Taraseviciene-Stewart, Laimute: 1 article (08/2005)
8.	Voelkel, Norbert F: 1 article (08/2005)

Related Diseases

1.	Right Ventricular Hypertrophy 08/01/2005 - "Taken together our data suggest that a stable bradykinin B2 agonist B9972 demonstrates the capacity to reduce severe pulmonary hypertension, right ventricular hypertrophy and induce apoptosis of hyperproliferative cells in pre-capillary pulmonary arterioles." 08/01/2005 - "Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy." 08/01/2005 - "Here we report that treatment of severely pulmonary hypertensive rats (that recapitulate several of the physiological and pathological characteristics of the human pulmonary vascular disease, including dramatic right ventricular hypertrophy, pericardial effusion and death) with a newly synthesized long-acting bradykinin B2 receptor agonist B9972 caused reduction of the pulmonary artery pressure (PAP=51+/-2.0 versus 68+/-2.8 of untreated animals) and of right ventricular hypertrophy (Rv/Lv+S=0.55+/-0.02 versus 0.73+/-0.03 of untreated rats) and activation of Akt. "
2.	Vascular Diseases (Vascular Disease) 08/01/2005 - "Here we report that treatment of severely pulmonary hypertensive rats (that recapitulate several of the physiological and pathological characteristics of the human pulmonary vascular disease, including dramatic right ventricular hypertrophy, pericardial effusion and death) with a newly synthesized long-acting bradykinin B2 receptor agonist B9972 caused reduction of the pulmonary artery pressure (PAP=51+/-2.0 versus 68+/-2.8 of untreated animals) and of right ventricular hypertrophy (Rv/Lv+S=0.55+/-0.02 versus 0.73+/-0.03 of untreated rats) and activation of Akt. "
3.	Pericardial Effusion 08/01/2005 - "Here we report that treatment of severely pulmonary hypertensive rats (that recapitulate several of the physiological and pathological characteristics of the human pulmonary vascular disease, including dramatic right ventricular hypertrophy, pericardial effusion and death) with a newly synthesized long-acting bradykinin B2 receptor agonist B9972 caused reduction of the pulmonary artery pressure (PAP=51+/-2.0 versus 68+/-2.8 of untreated animals) and of right ventricular hypertrophy (Rv/Lv+S=0.55+/-0.02 versus 0.73+/-0.03 of untreated rats) and activation of Akt. "
4.	Pulmonary Hypertension 08/01/2005 - "Taken together our data suggest that a stable bradykinin B2 agonist B9972 demonstrates the capacity to reduce severe pulmonary hypertension, right ventricular hypertrophy and induce apoptosis of hyperproliferative cells in pre-capillary pulmonary arterioles." 08/01/2005 - "Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy."

Related Drugs and Biologics

1.	Bradykinin B2 Receptor
2.	Bradykinin Receptors (Bradykinin Receptor)
3.	Bradykinin